PT-141 is a central melanocortin agonist studied across two Phase 3 trials in HSDD — here is what they actually measured.

The short version

Here is PT-141 in plain words. It is the research name for bremelanotide, a small lab-built peptide that switches on melanocortin MC3R/MC4R receptors (brain switches that influence sexual desire, appetite, and skin pigment). It is the first approved medicine that works on the brain's desire wiring rather than on blood flow. In 2019 the FDA approved it — as a 1.75 mg injection just under the skin (subcutaneous), taken as needed — for one thing only: HSDD (hypoactive sexual desire disorder, meaning persistent low sexual desire that causes real distress) in premenopausal women. Every other use — in men, for erectile difficulty — is off-label and still investigational. The trial benefit was real but modest, and nausea is the most common cost. This summarizes the published science; it is not medical advice.

PT-141 is the first centrally-acting, on-demand desire pharmacology

PT-141 is what happens when a synthetic peptide reaches the part of the brain that decides whether desire shows up at all. As bremelanotide injection it earned FDA approval in June 2019 (NDA 210557) for acquired, generalized HSDD in premenopausal women — the first and so far only drug approved on the principle of acting on sexual motivation in the central nervous system rather than on the plumbing of arousal ^[6]. That is the frontier this digest covers, and the boundary it keeps in view: the approval covers exactly one population and one indication, and nothing here treats off-label use as established.

The molecule is a synthetic analogue of alpha-MSH (alpha-melanocyte-stimulating hormone — a natural brain peptide), built as a cyclic ring of amino acids. It activates melanocortin receptors, chiefly MC4R, concentrated in the hypothalamus and limbic system. By stimulating MC4R in circuits such as the medial preoptic area, it is thought to engage dopaminergic pathways that govern sexual desire and arousal ^[1]. The contrast with the more familiar class of erectile drugs is the whole story: PDE-5 inhibitors (drugs such as sildenafil and tadalafil that improve erectile blood flow) act peripherally on blood vessels, while PT-141 acts on the neural circuitry of desire itself. That single mechanistic fact reorganizes how you read everything that follows — including the PT-141 clinical trial results, the PT-141 side effects, and the PT-141 for men literature.

The research record is unusually deep for a peptide in this space: dose-ranging studies in rats and nonhuman primates, two pivotal Phase 3 RCTs in women, a 52-week extension, mechanistic brain imaging, and a clearly-bounded set of off-label and early-phase signals. The approved regimen itself is concrete — the PT-141 dosage on the label is 1.75 mg subcutaneous, as needed, capped at one dose per 24 hours and eight per month, reported here as a label finding rather than guidance ^[6]. The optimism is earned by the data — and disciplined by it.

PT-141 Peptide: Structure and Identity

The PT-141 peptide is a 7-amino-acid cyclic lactam — sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, molecular weight 1025.2 Da, molecular formula C50H68N14O10, CAS 189691-06-3 ^[6]. The ring is closed by a lactam bridge between two side chains, and that cyclic architecture is the design move that matters: it confers greater stability than linear melanocortin peptides, which is part of why a once-as-needed injection works at all.

Structurally it is a close relative of melanotan II, but with the C-terminal amide swapped for a carboxylic acid — a small change with a meaningful consequence, shifting the profile toward the central desire effect that defines it. "Bremelanotide" is simply the international nonproprietary name (INN) for the same molecule developed as PT-141; the approved finished drug product is bremelanotide injection ^[6]. Material sold elsewhere as "PT-141 research chemical" is laboratory material only — not the approved finished drug — and carries no regulatory oversight of identity, purity, or concentration.

PT-141 Benefits: What the Phase 3 Endpoints Showed

In the approved population — premenopausal women with HSDD — bremelanotide met both coprimary endpoints in two identical Phase 3 trials. Integrated across the RECONNECT studies (n=1267), it improved sexual desire by +0.35 on the FSFI desire domain (P<.001) and reduced desire-related distress by -0.33 on FSDS-DAO item 13 (P<.001) versus placebo over 24 weeks ^[3]. (FSFI and FSDS are the standard questionnaires trials use to score sexual desire and the distress that low desire causes.) Those are statistically real findings — and honestly, they are clinically modest. Independent re-analyses argue the effect sizes are small enough to question their everyday meaningfulness, and this digest reports that debate rather than papering over it.

What are the benefits of PT-141?

In the approved population, bremelanotide produced statistically significant but clinically modest improvements in sexual desire and reductions in desire-related distress ^[3]. It acts centrally on sexual motivation rather than on blood flow ^[1]. The benefit is a shift in the desire and distress scores over months of as-needed use — not an on/off switch — and it applies only to premenopausal women with HSDD.

What PT-141 is, in four answers

What is PT-141?

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin MC3R/MC4R receptors ^[1]. As bremelanotide injection it is FDA-approved (June 2019) for HSDD in premenopausal women only ^[6]. Every other use is off-label.

What is PT-141 peptide?

A 7-amino-acid cyclic lactam peptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, structurally related to alpha-MSH, that acts as a melanocortin receptor agonist ^[6]. Its cyclic ring gives it more stability than a linear peptide of the same sequence.

What does the PT-141 peptide do?

It activates central MC4R (and MC3R) receptors in hypothalamic and limbic circuits that govern sexual desire and arousal, engaging dopaminergic signaling associated with appetitive sexual behavior rather than acting on vascular blood flow ^[1]. In female rats it selectively increased solicitational behavior without changing reflexive responses ^[2].

What is PT-141 used for?

Bremelanotide is approved only for acquired, generalized HSDD in premenopausal women ^[6]. Use in men, for erectile dysfunction, or in postmenopausal women is off-label, and the male/erectile evidence is early-phase and investigational only ^[1]. See PT-141 for men for that record.

How PT-141 works, and how it does not

Is PT-141 the same as bremelanotide?

Yes. "Bremelanotide" is the international nonproprietary name (INN) for the same melanocortin receptor agonist developed as PT-141; the approved finished drug product is bremelanotide injection ^[6]. The two names describe one molecule.

What is bremelanotide?

Bremelanotide is the FDA-approved (NDA 210557, 2019) melanocortin MC3R/MC4R receptor agonist indicated for HSDD in premenopausal women, administered as a 1.75 mg subcutaneous injection as needed ^[6]. It is the active ingredient in the approved product.

How does PT-141 work?

By stimulating MC4R in hypothalamic circuits such as the medial preoptic area, PT-141 is thought to engage dopaminergic pathways governing sexual desire and arousal ^[1]. Unlike PDE-5 inhibitors, it works centrally on the neural circuitry of sexual motivation, not peripherally on blood vessels ^[1]. A crossover brain-imaging study supports that central read ^[5]. For the full mechanism, see how PT-141 works.

A forward look without losing the boundary: PT-141 opened a genuinely new lane in sexual pharmacology — a centrally-acting, on-demand option where the prior toolkit was peripheral. The honest version of that excitement keeps two facts in frame at all times — the effect is modest, and the approval is narrow. Both live on the pages ahead, alongside every PT-141 questions answered.